SIMCHA THERAPEUTICS
Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer. The company uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system. Simchaโs lead program, ST-067, is a designer IL-18 cytokine that has shown potent antitumor effects in animal models, both as a monotherapy and when combined with anti-PD-1 checkpoint inhibitors, as described in Nature in June 2020. It was founded in 2018 and is headquartered in New Haven, Connecticut, USA.
SIMCHA THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science Pharmaceutical Therapeutics
Founded:
2018-01-01
Address:
New Haven, Connecticut, United States
Country:
United States
Website Url:
http://www.simchatx.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
65 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Wordpress Plugins
Similar Organizations
AffyImmune Therapeutics
AffyImmune Therapeutics is a biopharmaceutical company developing genetically engineered immune cells to fight cancer.
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Alladapt Immunotherapeutics
Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Ankyra
Ankyra is a biotech company developing anchored immunotherapy for cancer treatments.
Artiva Biotherapeutics
Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Calithera Biosciences
Calithera Biosciences is a pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer.
Checkmate Pharmaceuticals
Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.
CinCor Pharma
CinCor is a clinical-stage biopharmaceutical company that develops treatments for cardiovascular diseases.
Cybrexa Therapeutics
Cybrexa Therapeutics is a cancer therapeutics company developing a new class of small molecule DNA repair.
Eikonoklastes Therapeutics
Eikonoklastes Therapeutics is a preclinical-stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies.
Eirion Therapeutics
Eirion Therapeutics is a clinical-stage biopharmaceutical company that is developing next-generation prescription products.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
GentiBio
GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.
Immunic Therapeutics
Immunic is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies.
Intergalactic Therapeutics
Intergalactic Therapeutics is an ATP company, is revolutionizing gene therapies with a novel non-viral platform.
NMB Therapeutics
NMB Therapeutics is a pharmaceutical company that develops products to provide efficient drug delivery.
Ocumension Therapeutics
Ocumension Therapeutics is a pharmaceutical platform dedicated to identifying, developing, and commercializing ophthalmic therapies.
SpringWorks Therapeutics
SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.
Teon Therapeutics
Teon Therapeutics is a a biopharmaceutical company developing small molecules that inhibit the immunosuppressive cancer signaling pathways.
Third Harmonic Bio
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.
Umoja Biopharma
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.
Visen Pharmaceuticals
Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs.
Current Advisors List
Current Employees Featured
Founder
Investors List
SR One
SR One investment in Series B - Simcha Therapeutics
ArrowMark Partners
ArrowMark Partners investment in Series B - Simcha Therapeutics
BVF Partners
BVF Partners investment in Series B - Simcha Therapeutics
Logos Capital
Logos Capital investment in Series B - Simcha Therapeutics
Samsara BioCapital
Samsara BioCapital investment in Series B - Simcha Therapeutics
Rock Springs Capital
Rock Springs Capital investment in Series B - Simcha Therapeutics
Sequoia Capital China
Sequoia Capital China investment in Series A - Simcha Therapeutics
Connecticut Innovations
Connecticut Innovations investment in Series A - Simcha Therapeutics
Wuxi Venture Capital Group
Wuxi Venture Capital Group investment in Series A - Simcha Therapeutics
Official Site Inspections
http://www.simchatx.com Semrush global rank: 4.88 M Semrush visits lastest month: 1.8 K
- Host name: 93.26.196.104.bc.googleusercontent.com
- IP address: 104.196.26.93
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Simcha Therapeutics"
About - Simcha Therapeutics
About Innovative therapies that harness untapped immunobiology. Simcha Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies for cancer.See details»
Simcha Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer. The company uses directed โฆSee details»
SIMCHA THERAPEUTICS, INC. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for SIMCHA THERAPEUTICS, INC. of New Haven, CT. Get the latest business insights from Dun & โฆSee details»
Simcha Therapeutics - LinkedIn
Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics with transformational promise for patients.See details»
Simcha Therapeutics - VentureRadar
Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and โฆSee details»
Simcha Therapeutics - Company Profile - Tracxn
Oct 21, 2024 Email ID: *****@simchatx.com; Key Metrics. Total Funding. $65M in 2 rounds. Latest Funding Round. Series B, Jan 27, 2022, $40M. Investors. Connecticut Innovations & 8 โฆSee details»
Simcha Therapeutics - Craft
Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer. Its technology uses directed evolution to engineer novel cytokines โฆSee details»
Org Chart Simcha Therapeutics - The Official Board
For each of our 1,240,527 listed executives, discover their exact roles and their biographies.See details»
Culture & Careers - Simcha Therapeutics
Our Mission โAt Simcha, we develop transformative therapeutics to enhance patientsโ lives by harnessing the immune system to conquer cancer.โ Our Values Join Our Team Our focus is the patients we aim to serve If you are passionate โฆSee details»
Simcha Therapeutics - Research - Overview, Competitors, and
Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics with transformational promise for patients.See details»
Simcha Therapeutics - Overview, News & Similar companies
View Simcha Therapeutics (www.simchatx.com) location in Connecticut, United States , revenue, industry and description. Find related and similar companies as well as employees by title and โฆSee details»
Simcha Therapeutics Announces its Scientific Advisory Board, โฆ
SOUTH SAN FRANCISCO, Calif., and NEW HAVEN, Conn., โ August 22, 2023 โ Simcha Therapeutics (โSimchaโ), a clinical-stage immunobiology company pioneering first-in-class โฆSee details»
Simcha Therapeutics Shares Data at AACR Annual Meeting
Jun 25, 2020 A Phase 1 trial is expected to be launched in the first half of 2021. Simcha was founded by Aaron Ring, M.D., Ph.D., Assistant Professor of Immunobiology at the Yale School โฆSee details»
Simcha Therapeutics, Inc. (Simcha Therapeutics, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธ โฆ
Abstract Background: Interleukin-18 (IL18) is a proinflammatory cytokine that modulates both innate and adaptive immune responses. Historically, wild-type recombinant IL-18 has shown โฆSee details»
Simcha Therapeutics Shares Data at AACR Annual Meeting โฆ
Jun 25, 2020 For more information, visit www.simchatx.com. Contacts. Media Contact Stephanie Simon Ten Bridge Communications 617-581-9333 [email protected]. โฆSee details»
Contact - Simcha Therapeutics
Looking for more information? Contact us at [email protected]. Our locations New Haven, CTNew York, NYSouth San Francisco, CASee details»
Simcha Therapeutics Accelerates Growth with Key Leadership โฆ
Company Appoints Accomplished Biotech Leaders Sanuj Ravindran, M.D., as Chief Executive Officer and Jake Bauer as Independent Director and Chair NEW HAVEN, Conn., and SOUTH โฆSee details»
Press Releases Archives - Simcha Therapeutics
NEW HAVEN, Conn., and SOUTH SAN FRANCISCO, Calif. โ July 6, 2023 โ Simcha Therapeutics (โSimchaโ), a clinical-stage immunobiology company pioneering first-in-class โฆSee details»